TL;DR
Nine ingredients with enough recent evidence to genuinely retire in 2026. Ranked by strength of the data, not by social media panic. Six of these have moved because of EU regulatory updates or 2023-2025 peer-reviewed safety findings; three I keep on personal-preference grounds and say so.
Every year someone publishes a ‘toxic ingredients to avoid’ list and half of it is recycled fearmongering from 2012. I find these exhausting. The actual evidence base shifts. New data on retinyl palmitate photochemistry, new EU classifications, new long-term safety reviews. Some old worries collapse on review. Some new ones earn their place.
This is the 2026 working list. I went through it twice.
1. BHA (butylated hydroxyanisole) as a cosmetic preservative
Not to be confused with beta hydroxy acid. BHA is a synthetic antioxidant used to preserve fats in cosmetics. The EU Scientific Committee on Consumer Safety (SCCS) reclassified it as a CMR Category 1B substance in 2022. It was added to Annex II (prohibited list) in Regulation 2022/2195. The US has not followed. If you find BHA on a US label in 2026, it has been formally removed from EU shelves on carcinogenicity grounds.
2. Methylisothiazolinone (MI) in leave-on products
This is a preservative with one of the highest contact allergy rates ever recorded in cosmetics. Patch test positivity climbed to 10 to 13 percent in some European cohorts by 2014. The EU banned it in leave-on products in 2017. The US still allows it. A 2023 review in Contact Dermatitis confirmed the allergy rate has stabilized but not declined. If a moisturizer or serum contains MI in 2026, that is a formulation choice I find indefensible.
3. Hydroquinone, over-the-counter
The FDA removed OTC hydroquinone from the GRASE list in 2020 under the CARES Act. Prescription use under derm supervision is still appropriate for melasma. OTC formulas above 2 percent should not be on shelves. They still appear on imported products and some online sellers. Long-term unsupervised use is associated with exogenous ochronosis (a paradoxical, permanent darkening of skin). I would not touch OTC hydroquinone in 2026.
4. Retinyl palmitate in daytime products
The molecule itself is fine. The problem is photochemistry. A 2012 NTP study found retinyl palmitate increased UV-induced skin tumors in mouse models. Subsequent human data is mixed but suggestive. The conservative position is to keep retinyl esters on the night routine, which is what most dermatologists already recommend. If a daytime SPF contains retinyl palmitate in 2026, that is sloppy formulation.
5. Triclosan
FDA banned it in OTC antibacterial soaps in 2016 over endocrine disruption and antibiotic resistance concerns. Still appears in some toothpastes and a vanishingly small number of cosmetics. Retire it. The evidence is solid.
6. Lilial (butylphenyl methylpropional)
An EU CMR Category 1B reclassification in 2022 removed it from European cosmetics under Regulation 2021/1902. It is a fragrance allergen with reproductive toxicity concerns based on rodent studies. Quietly being reformulated out of global brands. I do not see it as often on US labels in 2026, but it is still legal here.
7. Coal tar in OTC anti-dandruff (personal-preference retirement)
This is where I split from the strict-evidence stance. Coal tar works for psoriasis and seborrheic dermatitis. The IARC classifies it as a Group 1 carcinogen for occupational exposure (much higher doses than cosmetic use). The cosmetic dose-response is not the same. But I would not recommend it for daily preventive use when ketoconazole and zinc pyrithione exist. Reserve coal tar for medical supervision.
8. PFAS (per- and polyfluoroalkyl substances) in long-wear makeup
An Environmental Science & Technology Letters 2021 paper (Whitehead et al.) found PFAS in 52 percent of long-wear cosmetics tested in the US and Canada. The EU is phasing PFAS out of cosmetics by 2026-2027. The persistence and bioaccumulation evidence is overwhelming. This is one where the environmental case is stronger than the direct skin case, but both matter.
9. Lead acetate in hair products (personal-preference retirement)
FDA banned its use in cosmetic hair dyes in 2018 after a long review. Still found in some imported products. Lead exposure has no safe threshold for cumulative neurological harm. The cosmetic dose is small. I still would not.
The contrarian take: most of the popular blacklist is wrong
Parabens, sulfates, mineral oil, silicones, and PEGs are not on this list because the actual evidence does not support retiring them. Parabens have a 60-year safety record at cosmetic concentrations. The 2004 Darbre breast tissue paper, which started the panic, has been heavily critiqued for methodological issues and was never replicated. Mixed feelings on the broader culture are fair, but the data on these is genuinely fine.
How I read evidence weight
Two questions. First, has a major regulator (EU SCCS, FDA, Health Canada) acted on it recently? Second, is there peer-reviewed mechanistic or epidemiological evidence published in the last five years? If both are yes, the ingredient earns retirement. If neither, the case is weak. If one of two, I weigh it and explain.
For more on label literacy, see our no-drama retirement list, the EU vs US regulation breakdown, and the claims to ignore piece.
FAQ
Are parabens on this list? No. The evidence does not support their retirement. The original methylparaben-in-breast-tissue paper from 2004 has been heavily critiqued and never replicated.
What about sulfates? Not on the list. Sulfates can be drying for some hair types and sensitive skin, but they are not a safety issue. That is a preference call.
Should I throw out products with these ingredients? Probably not throw out. Use them up if you have them and are not reactive. Replace at the next purchase.
How often does this list change? Annually. EU SCCS opinions and FDA OTC monograph updates are the two sources I check every December.
Why is the EU stricter? Different regulatory philosophy. The EU operates closer to a precautionary principle; the US is more reactive. Neither is purely right.
Tag hub: More on skincare myths and evidence
Sources
EU SCCS Opinion on BHA, SCCS/1636/21. National Toxicology Program. Retinyl Palmitate Photocarcinogenicity Study, NTP TR 568. Whitehead HD et al. Fluorinated compounds in North American cosmetics. Environ. Sci. Technol. Lett. 2021. FDA OTC Monograph removals, CARES Act 2020.